A Systematic Review of Health-Related Quality of Life Assessment Instruments for Cancer Patients: A Malaysian Perspective Introduction The absence of a review of health-related quality of life (HRQoL) assessment tools has led to inconsistencies in the use of HRQoL instruments across different cancer populations, such as adults, pediatric patients, and caregivers, limiting the comparability of findings and hindering the accurate evaluation of cancer care outcomes. With that, this study aimed to investigate how Malaysian cancer patients’ and other sub-population’s HRQoL is measured and quantified through HRQoL assessment instrument. Methods From 2013 to 2023, a literature search was conducted on Scopus, PubMed, Cochrane Library, and ClinicalTrials.gov. The included studies and previously published review papers were also cited backward. For each HRQoL assessment instrument, attributes such as author(s), year of publication, study site, study design, target population, cancer types, study purpose, sample size, and instrument languages were extracted and compared. Results In this systematic review encompassing 88 studies, a variety of HRQoL assessment tools were employed, including both generic and cancer-type specific instruments. Distinct HRQoL assessment tools were identified for different populations, including pediatric, adolescent, and caregiver groups. The findings underscore the wide variety of instruments used across different cancer populations and age groups, highlighting the need for tailored assessments that consider specific demographic and clinical contexts. While generic HRQoL tools were the most commonly used across studies, disease-specific instruments for various cancer types were also frequently employed as supplementary measures. Conclusion Moving forward, it is essential for stakeholders to collaborate in addressing the gaps in HRQoL research and to work towards the standardization of HRQoL assessment tools to ensure consistency and comparability in future studies.

Introduction: Untreated iron deficiency (ID) can lead to severe anaemia, requiring blood transfusion, or increased mortality risk. Globally intravenous (IV) iron is increasingly recognised as a recommended option for patients. This study aims to evaluate the budget impact associated with introducing a new intravenous (IV) iron, ferric derisomaltose (Monofer® [IIM]) as one of the treatment options for the management of ID in the Ministry of Health Malaysia (MOHM) setting. Methods: A 5-year budget impact model was developed from 2020 to 2024 for patients with ID that require a high iron dose (≥500 mg), using the perspective of MOHM. The model was built with four external medical specialists, each with experience and deep knowledge of ID management, to support estimations on the future development of iron use in Malaysia. Results: Compared to the current market mix with the existing IV iron products (i.e., iron sucrose and iron dextran), a cost-saving of MYR 53,910 could be achieved with the introduction of IIM in 2020. The uptake of IIM into MOHM over five years is estimated to lead to an overall budget saving of MYR 11,837,524 over a 5-year time horizon. Conclusion: The use of IIM in place of the current IV iron products in MOHM resulted in a significant cost saving by reducing the number of visits required to achieve the targeted iron dose and the shorter IV infusion time with IIM.